Head-to-head · WeighScore
Kin Meds vs No BS RX
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 69.1/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the Kin Meds review and the No BS RX review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.
If neither one fits, Kin Meds vs PCOS Sisters and Klinic vs No BS RX compare each of them with another graded program, and the list of alternatives to Kin Meds ranks the programs closest to Kin Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Direct Meds review covers one graded close to these two, at 77.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Kin Meds | No BS RX |
|---|---|---|
| WeighScore | 69.1/100 | 82.8/100 |
| Grade | C | B− |
| Site position | #147 | #23 |
| Semaglutide | Wegovy advertised from $149/mo; selected total unverified | $149/mo advertised for standard compounded injection; low-dose priced separately |
| Tirzepatide | Zepbound advertised from $149/mo; selected total unverified | $225/mo advertised for standard compounded injection; low-dose priced separately |
| Coverage | Coverage not published | Confirm program availability for your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Strengths
- Lists Wegovy and Zepbound on separate product pages
- Describes subscription cancellation through the patient account before shipment
What to consider
- The advertised starting price leaves the selected bill and insurance costs unverified
- The policy treats charged orders as final after carrier handoff
- Confirm service availability and dispensing pharmacy for your prescription
- FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.